Implants with absorbable and non-absorbable features for the treatment of female pelvic conditions

ABSTRACT

Described are methods, devices, and systems related to implants for the treatment of a female pelvic condition. The implants include absorbable and non-absorbable materials and can be introduced into the pelvic area transvaginally. Meshes of the invention provide benefits relating to improved tissue integration into the mesh, reduced infection likelihood, improved patient comfort following implantation, or combinations of thereof.

PRIORITY

This application is a continuation application of U.S. patentapplication Ser. No. 13/877,695, filed Apr. 4, 2013, issued as U.S. Pat.No. 9,468,512, which claims the benefit from International No.PCT/US2011/055092, which was granted an International Filing date ofOct. 6, 2011, which in turn claims the benefit of U.S. ProvisionalPatent Application Ser. No. 61/390,370, filed Oct. 6, 2010, entitledBIOABSORBABLE MESH FOR SURGICAL IMPLANTS, which applications areincorporated herein by reference in their entireties.

FIELD OF THE INVENTION

The present invention relates to implantable surgical meshes for thetreatment of a female pelvic condition, and more particularly, toimplantable surgical meshes that contain both absorbable andnon-absorbable materials. The implantable surgical meshes areparticularly useful for procedures involving a transvaginal insertion ofall or part of the mesh to a target pelvic area.

BACKGROUND

Implantable surgical meshes have been widely used for a variety ofdifferent surgical procedures such as hernia repair, pelvic floorrepair, urethral slings for treating fecal and urinary incontinence, andmany others.

For example, urinary incontinence is a disorder that generally affectswomen of all ages. The inability to control urination can impact asubject both physiologically and psychologically. Urinary incontinencecan interfere with a subject's daily activity and impair quality oflife. Stress urinary incontinence is one type of urinary incontinence.Actions including straining, coughing, and heavy lifting can cause womenwith stress urinary incontinence to void urine involuntarily.

Various physiological conditions cause urinary incontinence in women.Stress urinary incontinence is generally caused by two conditions thatoccur independently or in combination. One condition, known as intrinsicsphincter deficiency (ISD), occurs when the urethral sphincter fails tocoapt properly. ISD may cause urine to leak out of the urethra duringstressful actions. A second condition, known as hypermobility, occurswhen the pelvic floor is weakened or damaged and causes the bladder neckand proximal urethra to rotate and descend in response to increases inintra-abdominal pressure. When intra-abdominal pressure increases due tostrain resulting from coughing, for example, urine leakage oftenresults.

One method for treating stress urinary incontinence includes placing asling to either compress the urethral sphincter or placing a sling toprovide a “back stop” to the bladder neck and proximal urethra.Providing support to the bladder neck and proximal urethra maintains theurethra in the normal anatomical position, while elevation places theurethra above the normal anatomical position.

Other pelvic tissue disorders include cystocele, rectocele, enterocele,and prolapse such as vaginal vault prolapse. Pelvic disorders such asthese can result from weakness or damage to normal pelvic supportsystems. Due to the lack of support, structures such as the uterus,bladder, urethra, small intestine, or vagina, may begin to fall out oftheir normal positions. Conditions referred to as “conditions of thepelvic floor” include conditions caused by weakness or injury to pelvicfloor muscles, including levator muscles.

A cystocele is a medical condition that occurs when the tough fibrouswall between a woman's bladder and vagina (the pubocervical fascia) isweakened, such as by tearing, allowing the bladder to herniate into thevagina. A rectocele is a bulge of the front wall of the rectum into thevagina. The rectal wall may become thinned and weak, and it may balloonout into the vagina with pressure coming from the bowel. Enterocele is ahernia of the lining of the peritoneal cavity with or without abdominalviscera. The enterocele can occur posteriorly with or without inversionof the vagina.

Certain types of pelvic floor repair procedures, for example, caninvolve transvaginal access to internal tissue through a relativelysmall incision. Procedures can involve the transvaginal insertion of asupport member, such as a mesh sling or implant, for supporting specifictissue. The support member may include a central tissue support portionpositioned at tissue of a vaginal vault, and extension portions that aremoved through respective tissue pathways and their ends anchored attarget anatomical sites.

In a transvaginal procedure, portions of the implant are in contact withor pass through vaginal mucosal tissue, which is a unique anatomicalarea of the body and that presents some challenges for surgicalprocedures involving implanted meshes. The vaginal mucosa is lined bysquamous epithelium without any glands, and the subepithelial layercontains the vaginal blood vessels. Vaginal secretions contain vaginalepithelial cells and Doderlein's bacilli. Doderlein's bacillus is acommensal species that lives in the vagina, and the bacillus metabolizesglycogen in the vaginal epithelial cells, producing lactic acid. Thisreduces the vaginal pH to around 5.0 with is too low for many otherspecies including pathogens. Epithelial cells and bacillus that maybecome attached to the implant during or after the transvaginalprocedure are of concerns following surgical implantation/fixation. Forexample, epithelialization of implant surfaces can prevent desirabletissue in-growth and healing around the mesh.

Accordingly, there is need for improved implantable surgical meshes thatreduce or alleviate the problems associated with the treatment of femalepelvic conditions.

BRIEF SUMMARY OF THE INVENTION

Generally, the invention relates to an implant comprising a mesh portionand configured for transvaginal implantation and positioning in thepelvic area, the implant including non-absorbable and absorbablematerials. Embodiments of the invention provide benefits relating toimproved tissue integration into the mesh, reduced infection likelihood,improved patient comfort following implantation, or combinations ofthereof.

Implant embodiments of the current invention are configured fortransvaginal insertion into a pelvic area of a female patient for thetreatment of disorder or disease. The disorder or disease can beselected from, for example, urinary incontinence, vaginal prolapse,cystocele, and rectocele. Portions of the implant can have features tosupport an anatomical structure in the pelvis (i.e., a “supportportion”), such as the vagina, bladder, urethra, or levator ani.Portions of the implant can also have features, such as straps or armsthat extend from a support portion of the implant, or tissue anchors orfasteners (e.g., self-fixating tips), to help maintain the implant at adesired anatomical location in the pelvis.

In one embodiment, the invention provides an implant configured fortransvaginal insertion into a female patient to treat a pelvic disorder.The implant comprises a first non-absorbable mesh layer, and a secondabsorbable layer. The second absorbable layer is non-porous or lessporous than the first layer and prevents migration of cells through thesecond layer prior to its degradation in the body. Optionally, abioactive agent can be associated with the second absorbable layer

In a surgical procedure, the mesh can be implanted in the body using astep of transvaginally introducing all or a portion of the mesh into atarget area in the female pelvic region. In the method, the implanthaving first non-absorbable and second absorbable layers is provided. Anincision is made in the vaginal tissue, and then the mesh istransvaginally inserted into the patient so the second absorbable layerfaces the incision site. For example, the mesh is implanted so thenonporous absorbable polymer layer faces the suture line when theoriginal incision is closed. Following implantation, vaginal mucosaepithelial cells attach to the second absorbable layer, as the mesh isin contact with the vaginal tissue. The second absorbable layer preventsthe rapid epithelialization of the first non-absorbable mesh layer byproviding a barrier that degrades over time.

While epithelialization of the non-absorbable mesh (first layer) isbeing prevented by the second absorbable layer, tissue in-growth beginsto fill the pores of the non-absorbable mesh and can eventually surroundits structural features (e.g., filaments or molded cells) before theabsorbable film becomes porous. The second absorbable layer cantherefore reduce the exposure of small areas of mesh implants thatotherwise may become apparent a few weeks or months followingtransvaginal implantation. In many cases these “early” exposures mayotherwise occur at spots along the original incision line.Non-uniformities in wound closure may contribute to early meshexposures. The barrier function provided by the second absorbable layerdeters or prevents epithelialization that would otherwise hinder moredesirable tissue ingrowth into the first non-absorbable mesh layer.After a period of time, the second absorbable layer degrades anddesirable tissue in-growth occurs on the non-absorbable layer of themesh.

In another embodiment, the mesh includes a biological reagent that hasan effect on cellular material deposited from the vaginal mucosa on theimplant surface when the implant is transvaginally inserted into thepatient. Cells that can become deposed on the implant surface includemucosal epithelial cells and Doderlein's bacillus, and it can bedesirable to affect these cells as they may be carried internally intothe body from the vaginal mucosa during the transvaginal insertion.Alternatively, it can be desirable to affect internal tissue surroundingthe implant after the transvaginal insertion of the implant.

Therefore, in another embodiment, the invention provides an implantconfigured for transvaginal insertion into a female patient to treat apelvic disorder, wherein the implant includes a bioactive agent. Theimplant comprises a non-absorbable mesh, and an absorbable material,wherein absorbable material comprises a bioactive agent that is anantibiotic, antimicrobial, an inhibitor of epithelial cell activationand/or migration, or a compound that enhances wound regeneration. Theabsorbable material with bioactive agent is in the form of a coating onthe non-absorbable mesh, an absorbable filament associated with thenon-absorbable mesh, or a second layer associated with thenon-absorbable mesh. The type and configuration of the bioabsorbablematerial associated with the implant can be chosen so any significantamount of bioactive agent is not prematurely released from the implant,an event which may otherwise have an undesirable affect on cells of thevaginal mucosa. Release occurs after implantation where thebioabsorbable material has time to degrade and release the bioactiveagent to promote a desired biological effect. Optionally, a bioactiveagent can be associated with the absorbable material which canoptionally be present in the arms of the implant.

Another embodiment of the invention uses a combination of absorbable andnon-absorbable materials to reduce or eliminate long-termpost-implantation discomfort that may be experienced by a meshrecipient. Implantable meshes, such as those used in prolapse repair,can include a central mesh panel and “arms” that extend from the paneland pass through adjacent tissues to anchor the implant and providesupport while tissue in growth develops and matures in the centralpanel. In some meshes these anchoring arms pass through molded eyeletsthat enable the surgeon to adjust the position and tension applied tothe central panel during implantation.

Therefore, in another embodiment, the invention provides an implantconfigured for transvaginal insertion into a female patient to treat apelvic disorder, the implant comprising a central portion and two ormore arms that extend from the central portion, wherein the centralportion comprises a non-absorbable mesh, and the two or more armscomprise an absorbable material. Optionally, a bioactive agent can beassociated with the absorbable material of the arms of the mesh implant.Following implantation, the arms are used to help secure or position theimplant at a desired anatomical location in the pelvis. The arms providethis positioning support, but after a period of time, the bioabsorbablematerial in the arms degrades, thereby reducing the amount of syntheticmaterial in the body and providing better long term comfort to thepatient.

Use of absorbable material is also beneficial in that it can provideadditional structural support to the non-absorbable mesh portion duringan implantation step. This overcomes issues with some open weave or knitconstructions that promote tissue in-growth after implantation but donot necessarily lend sufficient structural support to the mesh to aid inthe process of implantation. Further, providing a closed-weave mesh thathas sufficient structural support for implantation does not necessarilyprovide sufficient porosity to promote tissue in-growth for long termstability.

DESCRIPTION OF THE DRAWINGS

FIG. 1 is an illustration of an implant having non-absorbable andabsorbable layers.

DETAILED DESCRIPTION OF THE INVENTION

All publications and patents mentioned herein are hereby incorporated byreference.

Implants of the invention are configured for transvaginal implantationand for female pelvic floor repair procedures. The implants can be usedto treat a disorder or disease selected from, for example, urinaryincontinence, vaginal prolapse, cystocele, and rectocele. As a generalmatter, the meshes include non-absorbable and absorb able materials. Onepart of the implant is a woven, knitted, or non-woven/non-knitted (e.g.,molded) non-absorbable mesh (e.g., mesh layer). Bioabsorbable materialcan be associated with the implant in the form of fibers, a thin sheetor film, or a coating. The associated bioabsorbable material prior toabsorption may lend additional structural support to the mesh forpurposes of implantation. The implants can have sufficient rigidity forimplantation, and in some constructions, sufficient openness in theweave pattern. The implant can be configured so the mesh issubstantially open to promote tissue-in growth.

Embodiments of the implants of the invention include a mesh portionconstructed from one or more nonabsorbable material(s). Exemplarynonabsorbable materials include synthetic polymers such as polyamides(e.g., nylons), fluoropolymers (e.g., polytetrafluoroethylene (PTFE) andpolyvinylidene fluoride (PVF)), and polyolefins (e.g. polypropylene andpolyethylene). In some aspects, polypropylene is used as a nonabsorbablematerial to form the mesh. Exemplary constructions use polypropylene,including isotactic and syndiotactic polypropylene, or blends thereof,to form the mesh. In some embodiments the implant has a knitted or wovenconstruction using polypropylene monofilaments (see, for example, U.S.Pat. No. 4,911,165). The mesh can be constructed from a monofilament ora multifilament yarn.

In other embodiments the implant includes a non-knitted/non-woven (e.g.,molded) polypropylene mesh layer (see, for example, commonly assignedPCT Publication Nos. WO2011/063412 and WO2011/072148).Non-knitted/non-woven meshes can be formed of patterned cells by way ofa molding, die casting, laser etching, laser cutting, extruding,punching, or 3-D printing process. The portion of the implant that isthe non-knitted/non-woven mesh can be considered a homogenous unitaryconstruct. The pattern cut or formed implant can be constructed of anon-absorbable polymer material to provide a lattice support structureof repeated cells. Repeated cells or patterns in the implant generallyform a lattice structure and can be cut or molded into sinusoid, orother waveform or undulating strut patterns to control elongation orcompression along single or multiple axes to define a desirable patterndensity with overall reduced surface area, and to control thedistribution and shaping from applied loads. In some aspects thethickness of the non-absorbable mesh is in the range from about 0.005inches to about 0.020 inches. In exemplary constructions, the mesh has awidth in the range of about 5 mm to about 15 mm, and a length from about6 cm to about 15 cm.

The implants of the invention also can include an “absorbable” material.The terms “bioabsorbable,” “degradable,” and “biodegradable,” can alsobe used to describe a material that is absorbable, such as an absorbablepolymer. Exemplary absorbable materials include polyhydroxyalkanoates,such as poly-4-hydroxybutyrate (P4HB), poly(3-hydroxyvalerate),polylactic acid, poly(lactide-co-glycolide), polycaprolactone,polyphosphazine, polyorthoesters, polyalkeneanhydrides, polyanhydrides,and polyesters, and the like. Polyhydroxyalkanoates include homopolymerssuch as poly-4-hydroxybutyrate (P4HB), poly(3-hydroxyvalerate), andhydroxyalkanoate copolymers such aspoly(hydroxybutyrate-co-hydroxyvalerate) (Organ, S. J. (1994) Polymer,35, 1:86-92) Blends of hydroxyalkanoate polymers with other absorbablepolymers have also been prepared, such as poly(β-hydroxybutyrate) andpoly(ε-caprolactone) blends (Gassner, F., and Owen, A. J. (1994)Polymer, 35, 10:2233-2236).

Polyhydroxyalkanoate polymer compositions useful for preparing implantsof the current invention are described in U.S. Pat. No. 7,268,205(William et al.) and U.S. Pub No. 20080132602 (Rizk et al.), theentireties of which is hereby incorporated by reference.Polyhydroxyalkanoate compositions, such as poly-4-hydroxybutyrate, canbe manipulated using processing techniques such as solvent casting, meltprocessing, fiber processing/spinning/weaving, extrusion, injection andcompression molding, and lamination, to prepare one or more portions ofthe implants of the current invention. Porous polyhydroxyalkanoatematerials can be prepared by the addition of a salt to a moltenpolyhydroxyalkanoate composition, followed by subsequent removal ofwater to remove the salt to leave a porous structure. Degradation of thepolyhydroxyalkanoate material can be increased by increasing theporosity of the material. In some aspects, the polyhydroxyalkanoatematerial of the mesh has an in vivo half-life of between three and sixmonths or less.

Polyhydroxyalkanoate films can be prepared as described in U.S. Pub No.20080132602 by solution casting techniques. Exemplarypoly-4-hydroxybutyrate films having thicknesses of less than 10 mm, lessthan 1 mm, and less than 100 μm are described. If desired, cast filmscan be stretched and oriented uniaxially or biaxially to yield thinnerand stronger films.

The polyhydroxyalkanoate can have a relatively low melting point/glasstransition temperature, for example, less than 136° C.Polyhydroxyalkanoate polymers can also be soluble in a non-toxic,non-halogenated solvent, such as 1,4-dioxane or tetrahydrofuran (THF).In some aspects, bioactive agent-containing polyhydroxyalkanoatecompositions can be prepared by including a drug that is soluble in thesolvent used to dissolve the polyhydroxyalkanoate. Alternatively, smallparticulates of bioactive agent, not dissolvable in thepolyhydroxyalkanoate solvent, can be homogenized in thepolyhydroxyalkanoate solvent. Materials, such as fibers or sheets, canbe formed from a melted polyhydroxyalkanoate composition, or asolvent-dissolved polyhydroxyalkanoate composition. In some embodimentsof the invention, a solvent-dissolved polyhydroxyalkanoate compositioncan be used for coating all or a portion of the implant.

In some embodiments, a bioactive agent is associated with the implant.In exemplary arrangements, the absorbable material with the bioactiveagent is in the form of an absorbable filament associated with thenon-absorbable mesh, a second layer (e.g., a film or sheet) associatedwith the non-absorbable mesh layer, or a coating on the non-absorbablemesh.

Exemplary biologically-active components include: growth factors,pro-angiogenesis factors, anti-fibrotic agents, anti-microbial agents,antibiotics, immuno-suppressive agents, inhibitors of epithelial cellactivation and/or migration, compounds that enhance wound regeneration,estrogen, other hormones, immunosupressants, anti-inflammatory agents,anti-cancer drugs, etc. For example, the bioactive agent can comprisethe ovarian steroid, estrogen or Estradiol, to treat vaginal prolapse.The design of the mesh can be optimized to allow optimum initialmechanical properties of the mesh and optimum release profiles of thebioactive agents after implantation. The fibers may inherently and/orartificially comprise biologically-active components. In someembodiments, the invention provides an implant that treats pelvic organprolapse, incontinence, or other urological disorders using theabsorbable material to modulate release of the bioactive agent followingtransvaginal implantation.

In one embodiment, the implant can increase the thickness of the vaginaltube by the controlled release of estrogen and/or an ovarian steroidhormone from an implant used to treat prolapse. Additionally, theimplant can allow for the remodeling of diseased tissues in order toprevent future recurrent prolapse. The implant embodiments of theinvention can provide local and targeted delivery of a bioactive agentat low dosages, and therefore can circumvent issues associated withsystemic therapies. The bioactive agent can be a simple formulation and,therefore, easy and inexpensive to manufacture.

The implant can deliver the bioactive agent locally to the desiredlocation within the pelvic area in order to treat a pelvic disorder,while mechanically supporting the structure(s) affected by the pelvicdisorder. The implant can controllably release the bioactive agent. Thedelivery device can degrade overtime, allowing the damaged tissues toremodel back into normal anatomical positions

The bioactive agent can comprise any drug or combination thereof totreat a specific pelvic disorder. In one embodiment, the bioactive agentcan comprise steroids. For example, the bioactive agent can comprise theovarian steroid, estrogen, to treat vaginal prolapse.

In some embodiments, the implant comprises a mesh formed from aplurality of absorbable fibers and a plurality of non-absorbable fibers,the mesh further associated with a bioactive agent. For example, themesh can include both non-absorbable and absorbable fibers that providemechanical and bioactive agent-release properties. The fibers can beknitted, woven, or molded. The non-absorbable fibers can be made ofpolypropylene.

The absorbable fibers can be made of any biocompatible syntheticmaterial, such as those described herein. An exemplary biocompatiblesynthetic material is that used in surgical sutures. A biological agentcan be included in the absorbable fibers in an amount to provide adesired biological effect in the body following implantation. Theeventual degradation of the absorbable fibers can provide for a lessdense and lighter sling system.

Exemplary meshes include a plurality of absorbable fibers including anabsorbable polyhydroxyalkanoate composition wherein the in vivodegradation rate of the fiber is controlled through the addition duringmanufacture of components to the polymeric composition, selection of thechemical composition, molecular weight, processing condition and form ofthe composition. A variety of knitted or woven patterns of the twofibers are also provided.

In exemplary meshes, a polypropylene non-absorbable fiber is knit orwoven together with a polyhydroxyalkanoate absorbable fiber. Thenon-absorbable fibers can be paired with a polyhydroxyalkanoateabsorbable fiber. The resulting paired fibers are then interwoven toform a bi-directional mesh structure prior to absorption of theabsorbable fibers. In another exemplary construction, the polypropylenenon-absorbable fibers can be aligned in a single direction along anX-axis while the plurality of absorbable fibers are interwoven with thenon-absorbable filaments along the Y-axis to thereby form abi-directional mesh structure prior to absorption of the absorbablefibers.

In another exemplary construction a polypropylene non-absorbable fiberis intermittently woven together with a polyhydroxyalkanoate absorbablefiber in an I-construction.

In another exemplary construction a polypropylene non-absorbable fiberis knit or woven together with a polyhydroxyalkanoate absorbable fiberto form a mesh sheet. The polypropylene non-absorbable fibers may bealigned in a single direction along an X-axis while the plurality ofabsorbable fibers may be interwoven with the non-absorbable filamentsalong the Y-axis. Alternatively, the plurality of absorbable fibers maybe aligned in a single direction along the X-axis while thenon-absorbable fibers are interwoven along the Y-axis. Polypropylenenon-absorbable fibers and polyhydroxyalkanoate absorbable fibers maythen run along an axis that is offset by about 45 degrees or more fromthe X and/or Y axes. Alternatively, the X and Y axis fibers may be thepolypropylene non-absorbable fibers while the fibers running on thethird axis may be exclusively polyhydroxyalkanoate absorbable fiber.

The meshes disclosed herein can be manufactured by any well knownweaving or knitting techniques. For example, weaving can use a shuttleloom, Jacquard loom or Gripper loom. In these looms the process ofweaving remains similar, the interlacing of two systems of yarns atright angles. This lacing can be simple as in a plain weave where thelacing is over one and under one. Placing the absorbable fibers in onedirection, either fill or wrap will result in a final remaining productof the non-absorbent fibers running in one direction. Alternatively, theplain weave may be configured in a more elaborate construction such astwill weave or satin weave.

Another method of weaving is a leno weave. In this construction two warpyarns are twisted and the fill yarns are passed through the twist. Inthis type of weaving the warp yarns can be polypropylene while the fillyarn is polyhydroxyalkanoate fibers. Alternatively, for a more openconstruction the warp yarns can be polyhydroxyalkanoate while the fillyarn is polypropylene. Those skilled in the art will appreciate thatadditional variations of the basic weaves such as, sateen weaves,antique satin, warp faced twills, herringbone twills and the like can beused to create woven fabrics that will produce the same results when oneof the directional yarns absorbs.

Other types of meshes can be constructed by knitting, which is a processof making cloth with a single yarn or set of yarns moving in only onedirection. In weaving, two sets of yarns cross over and under eachother. In knitting, the single yarn is looped through itself to make thechain of stitches. One method to do this is described as weft knitting.Knitting across the width of the fabric is called weft knitting.

Whether a woven or knit mesh is chosen, the ratio of absorbable tonon-absorbable yarns can be adjusted. This will provide differentamounts of structural integrity of the resulting mesh. For example,using pairs of non absorbable fibers and absorbable fibers would producea final fabric, after absorption, with a larger open space between thenon-absorbable fibers. Variations on this type construction will producea remaining fabric, which promotes either more of less scar tissuedepending on the amount of fabric and distance between sections. Thiscan be adjusted for the type of tissue, which is being replaced. Alighter tissue, such as a fascia for supporting or connecting organs,can use a knitted mesh that has a wider section of absorbable and anarrower section of non-absorbable fibers.

A second method for knitting a fabric or mesh is warp knitting. In thismethod the fibers are introduced in the direction of the growth of thefabric (in the y direction). Warp knitting is a family of knittingmethods in which the yarn zigzags along the length of the fabric, i.e.,following adjacent columns (“wales”) of knitting, rather than a singlerow (“course”). In this type of knitting the fibers are loopedvertically and also to a limited extent diagonally, with the diagonalmovement connecting the rows of loops. As with the weft knit fabrics,alternate yarns can be absorbable or non-absorbable. Controlling thenumber and ratio of absorbable to non-absorbable fibers will control thefinal material configuration and again the amount of tissue in-growth.Alternating absorbable and non-absorbable fibers produces a finalconstruction with a narrow space between the remaining yarns which arefilled in with tissue. As with woven fibers and meshes, the warp knitscan be adjusted to create various amounts of tissue in-growth.

In another embodiment non-absorbable fibers, such as polypropylenefibers, are knit or woven together to form a mesh. The openings in themesh are intermittently or completely filled with an absorbablematerial, such as a polyhydroxyalkanoate material. Depending on theinitial degree of stiffness or rigidity that is required, apolyhydroxyalkanoate material may be used as a hot-melt glueintermittently at the intersecting portions of the polypropylene fibers.Alternatively the polyhydroxyalkanoate material may be used at allintersecting points. The absorbable composition that is filled into theopenings in the mesh can also include a bioactive agent.

In this aspect, the absorbable material could be filled in so that it ispresent predominantly on one side of the mesh and forms a second,protective layer that shields the non-absorbable mesh from epithelialcell attachment following implantation. Alternatively, the absorbablematerial can be filled into the mesh so that it forms a glue for theattachment of a second, protective, absorbable layer. For example, thepolyhydroxyalkanoate material can be coated on the polypropylenenon-absorbable fibers to form a sheath, which, in addition to providinga barrier to epithelialization of the polypropylene mesh followingimplantation, functions as a cushion between the stiff polypropylenefilaments and the tissue thereby reducing erosion problems.

An implant with a first non-absorbable mesh layer, and a secondabsorbable layer that is non-porous or less porous than the first layerand prevents migration of cells through the second layer prior to itsdegradation in the body can be formed by attaching a thin absorbablefilm or sheet, such as formed by solvent casting herein, to anon-absorbable mesh. FIG. 1 illustrates such a mesh 10 showing a firstnon-absorbable layer 12, which can be prepared from a non-absorbablepolymer, such as a polypropylene. One exemplary construction uses amolded polypropylene mesh layer. Another exemplary construction uses anonabsorbable, large pore, monofilament, mesh. Preferably, the firstlayer has a thickness in the range of about 0.005 inches to about 0.020inches, other preferred features or properties of the first absorbablelayer are: porosity, flexibility/stiffness, etc.

The second absorbable layer 14, can be prepared from a singlebioabsorbable polymer, such as a polyhydroxyalkanoate likehydroxybutyrate, or blend of bioabsorbable polymers. One exemplaryconstruction uses a thin film of absorbable material prepared by solventcasting, such as described herein. Followings its introduction into thebody, the second absorbable layer is impervious to cells, such asepithelial cells, from the vaginal incision site. After implantation,the second absorbable layer begins to erode and eventually allows cellsto pass to the first non-absorbable layer. In some modes of practice,the second absorbable layer erodes and allows the passage of cells in aperiod of time in the range of about two weeks to about six months.However, in the time it takes for the second absorbable layer to erodeand allow the passage of cells, non-epithelial cells and tissue healingcomponents infiltrate the pores of the non-absorbable mesh layer andgenerate desirable tissue in-growth.

The first and second layers can be associated with each using one ormore different techniques. In one exemplary construction, an absorbableadhesive is used to cause the first non-absorbable mesh layer to adhereto the second absorbable layer. For example, a hot melt adhesiveincluding absorbable polymer can be used at selected points between thefirst and second layers. The adhesive can use either the same absorbablepolymer as the second absorbable layer, or a different absorbablepolymer formulation.

The implant can also include mechanical features to associate the firstand second layers. For example, the second absorbable layer can beformed with regularly-spaced protruding features on one surface. Theseprotruding features can be shaped and spaced to interact with thefeatures of the first non absorbable mesh, such as large pore meshfeatures made using monofilaments. This type of attachment is thereforesimilar to that of conventional hook and loop fasteners.

The attachment feature (e.g, such as an adhesive or mechanical feature)can be formulated to absorb more rapidly in vivo than the secondabsorbable layer. This ensures substantial or complete tissue ingrowthin the first non-absorbable layer before fissures appear in theabsorbable film layer. In some cases the second absorbable layer isformed from an absorbable homopolymer, and the attachment featureincludes an absorbable copolymer that has a rate of degradation that isfaster than the homopolymer. The homopolymer and copolymer can share acommon monomer, such as a hydroxyalkanoate like hydroxybutyrate. Othercopolymer types, for example, copolymers of ε-caprolactone withdl-lactide have been synthesized to yield materials with rapiddegradation rates.

In yet another embodiment, an apparatus for treating urinaryincontinence in a female subject comprises a urethral sling having acentral portion and first and second ends or arms. The first and secondends/arms are coupled to and extend from the central support portion.The central support portion is comprised of a mesh knit or woven fromnon-absorbable fibers or a non-woven/non-knitted (e.g., molded) mesh(and optionally including bioabsorbable material), while the first andsecond ends comprise absorbable material, such as absorbable fibers oran absorbable sheet. In some embodiments, the end portions comprise amesh including bioabsorbable and non-absorbable fibers while the centralportion comprises non-absorbable fibers. Following implantation, thearms are used to help secure or position the implant at a desiredanatomical location in the pelvis. The arms provide this positioningsupport, but after a period of time, the bioabsorbable material in thearms degrades, thereby reducing the amount of synthetic material in thebody and providing better long term comfort to the patient.

Implants of the invention can be part of a kit. The kit can includecomponents for carrying out procedures for the insertion of the implantin a female patient. Exemplary components can include tissue fasteners,tools for introducing the implant into a female using a transvaginalinsertion procedure, scalpels or knives for making the incision, andneedles and suture material for closing the incision. All or parts ofthe kit can be sterilely packaged. Insertion tools useful fortransvaginal insertion of the implant can include a handle and anelongate needle, wire, or rod extending from the handle. The needle,wire, or rod can be shaped (such as helical, straight, or curved) to beuseful to carry the implant through a desired tissue path in the pelvicregion.

The particular features of the implant embodiments of the invention canbe adapted to known mesh implant constructions useful for treatingfemale pelvic conditions, including those already described in the art.Those skilled in the art will recognize that various other meshconfigurations, such as those described herein with reference to thefollowing publications, can also be used in conjunction with thefeatures and procedures of the current invention.

In some constructions, the implant is used for treating incontinence,prolapse, or a mixture of incontinence and prolapse, and includes aportion useful to support the urethra or bladder neck to address urinaryincontinence, such as described in commonly assigned applicationpublished as US 2010/0256442 (Ogdahl, et al.), and exemplified by themesh constructions of FIGS. 3B and 3C therein. The implant can be in theform of a mesh strip that in inserted transvaginally and used to supportthe urethra or bladder neck. The implant can be configured to have alength (distance between distal ends, e.g., self-fixating tips, ofextension portions) to extend from a right obturator foramen to a leftobturator foramen, (e.g., from one obturator internus muscle to theother obturator internus muscle). Exemplary lengths of an implant orimplant portion for extension below the urethra, between opposingobturator foramen, from distal end to distal end of the extensions whilelaying flat, can be in the range from about 6 to 15 centimeters, e.g.,from 7 to 10 centimeters or from 8 to 9 centimeters or about 8.5centimeters. (Lengths L1 and L2 of FIGS. 3B and 3C can be within theseranges.) The lengths are for female urethral slings, and are foranterior portions of implants for treating female prolapse or combinedfemale prolapse and incontinence, which include an anterior portion thathas a length between ends of anterior extensions portions within thesesame ranges. A width of the extension portion can be as desired, such aswithin the range from about 1 to 1.5 centimeters. The implant can alsohave two or more tissue anchoring features (e.g., self-fixating tips).The self-fixating tips can be present at the ends of the mesh strips, orat the ends of arms or extensions that extend from a central supportportion.

In some constructions, the mesh can be configured to treat pelvicconditions by supporting levator muscle, such as described in commonlyassigned application published as US 2010/0261952 (Montpetit, et al.).The levator musculature or “levator ani” can include the puborectalis,pubococcygeus, iliococcygeus. Exemplary implants can be of a size andshape to conform to levator tissue, optionally to additionally contactor support other tissue of the pelvic region such as the anal sphincter,rectum, perineal body, etc. The implant can be of a single or multiplepieces that is or are shaped overall to match a portion of the levator,e.g., that is circular, oblong trapezoidal, rectangular, that contains acombination of straight, angled, and arcuate edges, etc. The implant caninclude attached or separate segments that fit together to extend besideor around pelvic features such as the rectum, anus, vagina, and thelike, optionally to attach to the feature. The implant can include atissue support portion, which at least in part contacts levator tissue.Optionally, the implant can additionally include one or more extensionportion(s) that extends beyond the tissue support portion and to besecured to tissue of the pelvic region, for support of the tissuesupport portion. Optionally, extension portions can include featuressuch as a tissue fastener (e.g., self-fixating tip, soft tissue anchor,bone anchor, etc.), a sheath, a tensioning mechanism such as a suture,an adjustment mechanism, etc.

According to exemplary methods, an implant for supporting levator musclecan be introduced through a vaginal incision that allows access tolevator tissue. The method can include use of an insertion tool designedto reach through a vaginal incision, through an internal tissue path andto then extend through a second external incision. In some cases, a toolis used to place a self-fixating tip at an internal location of thepelvic region. The tool can have a length sufficient to reach from avaginal incision to one of an obturator foramen, a region of the ischialspine, a sacrospinous ligament, or other location of placing aself-fixating tip. Exemplary methods include steps that involve creatinga single medial transvaginal incision and dissecting within a plane orregion of dissection including the ischorectal fossa. An implant can beinserted to contact tissue of the levator, over a desired area. A kitwith the implant can include connectors for engagement between a needleof an insertion tool and a distal end of an extension portion, as wellas helical, straight, and curved needles. An embodiment of a kit,including an insertion tool and an implant, is shown in FIG. 5 of US2010/0261952.

The implant can include self-fixating tips designed to engage a distalend of an insertion tool to allow the insertion tool to place theself-fixating tip at a desired tissue location by pushing. For example,the mesh can be implanted by creating a single medial transvaginalincision under the mid-urethra, dissecting a tissue path on each side ofthe incision, passing a urinary incontinence sling through the incisionwhereby the urinary incontinence sling is suspended between theobturator internus muscles and the sling body is positioned between thepatient's urethra and vaginal wall to provide support to the urethra.Commonly assigned application published as US 2011/0034759 (Ogdahl, etal.), also describes implants that include a self-fixating tip at adistal end of one or more extension portions, and transvaginal methodsfor inserting the mesh into a patient.

In some constructions, the mesh can be configured to treat vaginalprolapse, including anterior prolapse, posterior prolapse, or vaultprolapse such as described in commonly assigned application published asUS 2010/0261955-A1 (O'Hern, et al.). The mesh can be insertedtransvaginally, following a single incision in the vaginal tissue, withno external incision. The mesh can be used to provide Level 1 support ofthe vaginal apex in combination with Level 2 support of medial vaginalsidewall tissue. In terms of vaginal prolapse, Level 1 vaginal tissuesupport relates to support of the top portion, or “apex” of the vagina.This section of tissue is naturally supported by the cardinal ligamentthat goes laterally to the ischial spine and crosses over medially tothe sacrospinous ligament, and also by the uterosacral ligament thatanchors into the sacrum. Level 2 support of vaginal tissue is support oftissue of the mid section of the vagina, below the bladder. This tissueis partially supported by the cardinal ligament but is predominantlysupported by lateral fascial attachments to the arcus tendineus or whiteline. Level 3 support is that of the front end (sometimes referred to asthe “distal” section) of the vagina right under the urethra. Naturalsupport includes lateral fascial attachments that anchor into theobturator internus muscle.

The method for inserting the implant for treating vaginal prolapse caninclude providing an implant that includes a tissue support portion andtwo or more extension portions; placing the tissue support portion incontact with vaginal tissue to support the vaginal tissue; and extendinga posterior extension portion to engage a sacrospinous ligament, andextending a lateral extension portion to engage tissue at a region ofischial spine, or extending a posterior extension portion to engage asacrospinous ligament, and extending an anterior extension portion toengage an obturator foramen, or extending an extension portion to engagea sacrospinous ligament to provide Level 1 support, and supportingvaginal tissue to provide Level 2 support. FIG. 16 of US-2010-0261955-A1illustrates a kit with an implant having a support portion piece, twoextension portion pieces, adjusting tool, grommet management tool, andinsertion tool.

In some modes of practice, the implants of the invention can be usedalong with an expansion member in a sacral colpopexy is a procedure forproviding vaginal vault suspension, such as described in commonlyassigned International Application No. PCT/US2011/053985, published asWO/2012/050973. A sacral colpopexy generally involves suspension, suchas by use of a mesh strip implant, of the vaginal cuff to a region ofsacral anatomy such as the sacrum (bone itself), a nearby sacrospinousligament, uterosacral ligament, or anterior longitudinal ligament at thesacral promontory. The implant can be utilized in a transvaginal sacralcolpopexy (TSCP) procedure with an expansion member to access tissue ofthe posterior pelvic region.

Implants can be prepared including a mesh that is low-density,bioactive, and image-capable. The low-density mesh relieves stress atthe points of attachment. The bioactive mesh biologically treats andrepairs the pelvic condition. The mesh can also be image-capable so thatthe implant can be visualized after implantation.

In some constructions, the non-absorbable fibers can comprise wire,allowing for the visualization of the implant after implantation. Thewire can be made of fine tantalum and/or any other material known by aperson skilled in the art and can be woven together with monofilamentsof polypropylene or other polymers to create surgical meshes. In someconstructions, the mesh can comprise radiopaque ink, allowing for thevisualization of the entire mesh. The wire and/or radiopaque ink canprovide imaging capability without extensive developmental work.Further, the wire and radiopaque ink do not substantially alter themechanical properties of the existing mesh. Nor do the wire andradiopaque ink substantially alter local tissue response.

These and other features and advantages and embodiments of the presentinvention will become apparent from the following this description, whentaken in conjunction with the accompanying drawing which illustrate, byway of example, the principles of the invention. It will be furtherapparent from the foregoing that other modifications of the inventionsdescribed herein can be made without departing from the spirit and scopeof the invention.

What is claimed is:
 1. An implant configured for transvaginal insertioninto a female patient to treat a pelvic disorder or disease, the implantcomprising: a non-absorbable mesh layer, the non-absorbable mesh layerincluding an absorbable material, the absorbable material being abioactive agent that is selected from at least one of an antibiotic, anantimicrobial, an inhibitor of epithelial cell activation, a migration,or a compound that enhances wound regeneration, the absorbable materialbeing in a form of at least one of a coating on the non-absorbable meshlayer, an absorbable filament associated with the non-absorbable meshlayer, or a second layer associated with the non-absorbable mesh layer;an absorbable layer, the absorbable layer being formed from abioabsorbable polymer, the absorbable layer has a rate of degradationthat is faster than a rate of degradation of the absorbable material inthe non-absorbable mesh layer; and an attachment member disposed on theabsorbable layer, the attachment member being configured to absorb morerapidly in vivo than the absorbable layer.
 2. The implant of claim 1,wherein the bioactive agent is estrogen or estradiol.
 3. The implant ofclaim 2, further comprising a second bioactive agent selected from thegroup consisting of an antibiotic, an antimicrobial, an inhibitor ofepithelial cell activation and/or migration, epidermal grown factor(EGF), transforming growth factor α or β (TGF-α or β), vascularendothelial growth factor, platelet derived growth factor, andfibroblast growth factor.
 4. The implant of claim 1, wherein thebioactive agent diffuses from or is released from the absorbablematerial upon degradation of the absorbable material.
 5. The implant ofclaim 1, wherein the absorbable material comprises a hydroxyalkanoatepolymer.
 6. The implant of claim 5, wherein the absorbable materialfurther comprises polyhydroxybutyrate.
 7. The implant of claim 1,wherein the absorbable material comprises a polyester copolymer.
 8. Theimplant of claim 7, wherein the polyester copolymer has a rate ofdegradation that is faster than the bioabsorbable polymer which is ahydroxyalkanoate polymer.
 9. The implant of claim 8, wherein thebioabsorbable polymer further comprises a bioactive agent selected fromthe group consisting of an antibiotic, an antimicrobial, an inhibitor ofepithelial cell activation and/or migration, epidermal grown factor(EGF), transforming growth factor α or β (TGF-α or β), vascularendothelial growth factor, platelet derived growth factor, andfibroblast growth factor.
 10. The implant of claim 1, wherein theabsorbable material further comprises an absorbable polyester thatincludes one or more monomer(s) selected from the group consisting ofhydroxyalkanoate, lactide, glycolide, and caprolactone.
 11. The implantof claim 1, wherein the absorbable layer is non-porous and preventsmigration of cells through the absorbable layer prior to degradation ofthe absorbable layer within a female patient.
 12. The implant of claim11, wherein the absorbable layer has a thickness in a range of 0.005 to0.02 inches.
 13. The implant of claim 11, wherein the attachment memberis an absorbable adhesive or protruding member, wherein the attachmentmember includes an absorbable material that has a rate of degradationthat is faster than the bioabsorbable polymer of the absorbable layer.14. The implant of claim 13, wherein the absorbable layer has a sideportion in contact with the non-absorbable mesh layer, the absorbablelayer including the absorbable adhesive or the protruding member that isconfigured to secure the non-absorbable mesh layer to the absorbablelayer.
 15. The implant of claim 11, wherein the absorbable layercomprises an absorbable material in a form of a coating.
 16. The implantof claim 1, wherein the non-absorbable mesh layer comprisespolypropylene filaments or molded polypropylene.
 17. The implant ofclaim 1, the implant further comprising: a central portion and two ormore arms that extend from the central portion, wherein the centralportion comprises the non-absorbable mesh layer, and the two or morearms comprise the absorbable material.
 18. A method for surgicallyimplanting a mesh in a female patient to treat a pelvic disorder ordisease, the method comprising: (a) providing an implant, the implantincluding: a non-absorbable mesh layer, the non-absorbable mesh layerincluding an absorbable material, the absorbable material being abioactive agent that is least one of an antibiotic, an antimicrobial, aninhibitor of epithelial cell activation, a migration, or a compound thatenhances wound regeneration, the absorbable material being in a form ofat least one of a coating on the non-absorbable mesh layer, anabsorbable filament associated with the non-absorbable mesh layer, or asecond layer associated with the non-absorbable mesh layer; anabsorbable layer, the absorbable layer being formed from a bioabsorbablepolymer, the absorbable layer has a rate of degradation that is fasterthan a rate of degradation of the absorbable material in thenon-absorbable mesh layer; and an attachment member disposed on theabsorbable layer, the attachment member being configured to absorb morerapidly in vivo than the absorbable layer; (b) creating an incision invaginal tissue of the female patient; and (c) transvaginally insertingthe implant into the female patient so the absorbable layer faces theincision site, wherein the implant treats the pelvic disorder ordisease.
 19. The method of claim 18, wherein the bioactive agent isreleased from the implant to remodel tissue, to reduce infectionlikelihood, or both.